IA
ALXN

Icon Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Icon Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,182
Closed -$3.39M – 245
2020
Q2 		$3.39M Sell
30,182
-3,851
-11% -$409K 0.66% 40
2020
Q1 		$3.06M Sell
34,033
-2,800
-8% -$275K 0.67% 37
2019
Q4 		$3.98M Hold
36,833
– – 0.57% 54
2019
Q3 		$3.61M Sell
36,833
-3,800
-9% -$428K 0.53% 53
2019
Q2 		$5.32M Sell
40,633
-4,700
-10% -$606K 0.5% 60
2019
Q1 		$6.13M Sell
45,333
-13,591
-23% -$1.69M 0.62% 47
2018
Q4 		$5.74M Buy
58,924
+13,924
+31% +$1.65M 0.6% 50
2018
Q3 		$6.25M Buy
45,000
+8,600
+24% +$1.08M 0.53% 60
2018
Q2 		$4.52M Hold
36,400
– – 0.34% 81
2018
Q1 		$4.06M Hold
36,400
– – 0.31% 92
2017
Q4 		$4.35M Buy
36,400
+2,400
+7% +$292K 0.3% 94
2017
Q3 		$4.77M Buy
34,000
+17,600
+107% +$2.39M 0.33% 102
2017
Q2 		$2M Buy
+16,400
New +$1.91M 0.14% 199
2016
Q4 		– Sell
-21,900
Closed -$2.68M – 460
2016
Q3 		$2.68M Buy
21,900
+1,900
+10% +$245K 0.18% 172
2016
Q2 		$2.33M Buy
+20,000
New +$2.84M 0.16% 177
2016
Q1 		– Sell
-6,400
Closed -$1.22M – 388
2015
Q4 		$1.22M Sell
6,400
-5,400
-46% -$943K 0.08% 216
2015
Q3 		$1.84M Sell
11,800
-53,450
-82% -$9.75M 0.13% 164
2015
Q2 		$11.8M Buy
65,250
+33,450
+105% +$5.77M 0.74% 43
2015
Q1 		$5.51M Buy
31,800
+15,400
+94% +$2.79M 0.32% 103
2014
Q4 		$3.03M Sell
16,400
-8,000
-33% -$1.48M 0.18% 129
2014
Q3 		$4.05M Buy
24,400
+10,000
+69% +$1.64M 0.24% 112
2014
Q2 		$2.25M Buy
+14,400
New +$2.27M 0.14% 137
2013
Q4 		– Sell
-44,085
Closed -$5.12M – 348
2013
Q3 		$5.12M Sell
44,085
-14,000
-24% -$1.54M 0.39% 65
2013
Q2 		$5.36M Buy
+58,085
New +$5.6M 0.41% 58

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Icon Advisers's ALXN Position: Q3 2020 in Review

Icon Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 30,182 shares — an estimated $3.39M sold.

Icon Advisers first reported a position in ALXN in Q2 2013 and held it in 24 quarters. The position peaked at $11.8M in Q2 2015. 709 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Icon Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Icon Advisers sold 30,182 Alexion Pharmaceuticals shares in Q3 2020, an estimated $3.39M.
  • Icon Advisers first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Icon Advisers's Alexion Pharmaceuticals position peaked at $11.8M in Q2 2015.
  • 709 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Icon Advisers's 13F filing for Q3 2020, filed 5 Nov 2020.